title: Evidence Corner: Evidence-based Care for Malignant Wounds.
abstract: Malignant fungating wounds occur in 5% to 10% of individuals with cancer.1 They arise "when malignant tumour cells infiltrate and erode through the skin."2 Guidelines for treating these malignant wounds (MW) often lack randomized, clinical trial (RCT) evidence supporting local wound care interventions that meet patients' physical or psychosocial needs or facilitate healing.3 The rarity of RCTs exploring healing of MWs likely results from their very low expectation of complete closure.1 Affected patients and their professional and family caregivers rate pain, infection, and odor management among the most important challenges in minimizing distress.4-6 Though a recently updated Cochrane review3 reminds us that evidence remains insufficient for firm conclusions supporting management of MW, it does cite 2 recent RCTs described herein7,8 that can serve as "current best evidence"9 to inform clinical decisions for alleviating some aspects of these patients' distress.
authors.affiliation: Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
authors.forename: Laura
authors.initials: L
authors.lastname: Bolton
mesh_terms: D001684:Biological Dressings; D018450:Disease Progression; D004311:Double-Blind Method; D019317:Evidence-Based Medicine; D005122:Exudates and Transudates; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000473:pathology / Q000628:therapy; D018030:Silver Compounds / Q000008:administration & dosage*; D017592:Skin Care / Q000379:methods*; D012883:Skin Ulcer / Q000150:complications / Q000473:pathology / Q000628:therapy; D014945:Wound Healing; D014947:Wounds and Injuries / Q000150:complications / Q000473:pathology* / Q000628:therapy*
chemical_list: D018030:Silver Compounds